This is a real-world medical entrance exam question, please give the true answer based on the question and selection. Topic name: NSAIDs, Gout and Rheumatoid Ahritis, Subject name: Pharmacology
Which of the following is not a new drug for Migraine? 
Select and explain. 
A. Lasmiditan, B. Ubrogepant, C. Rimegepant, D. Romosozumab
D: Romosozumab
Answer: D: Romosozumab 
Explanation: Option 1 Lasmiditan Highly affinity for 5-HT1Freceptor agonist Acts on trigeminal system without causing vasoconstriction Low affinity for 5-HT1Breceptors Acute therapy for migraine in patients with cardiovascular risk factors Option 2 Ubrogepant Calcitonin gene related peptide (CGRP) receptor antagonist Acute treatment of migraine attacks Option 3 Rimegepant Only CGRP antagonists that possess oral bioavailability Acute treatment migraine headache Option 4 Romosozumab Sclerostin inhibitor Treatment of osteoporosis in postmenopausal women at high risk for fracture Monoclonal antibodies that antagonize the CGRP pathway are: Galcanezumab Eptinezumab Fremanezumab(which all target the CGRP peptide) Erenumab ( fully human mAb designed to target the CGRP receptor). =Standard migraine Rx involves "triptans", but these are C/I in patients with pre-existing cardiovascular disease due to their vasoconstrictive propeies.